

# Yu-Shan Huang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6724993/yu-shan-huang-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

327  
citations

11  
h-index

16  
g-index

40  
ext. papers

483  
ext. citations

7.2  
avg. IF

3.36  
L-index

#	Paper	IF	Citations
36	Comparing visual inspection, aerobic colony counts, and adenosine triphosphate bioluminescence assay for evaluating surface cleanliness at a medical center. <i>American Journal of Infection Control</i> , <b>2015</b> , 43, 882-6	3.8	37
35	Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179870	3.7	25
34	Treatment of <i>Pneumocystis jirovecii</i> pneumonia in HIV-infected patients: a review. <i>Expert Review of Anti-Infective Therapy</i> , <b>2017</b> , 15, 873-892	5.5	23
33	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. <i>EClinicalMedicine</i> , <b>2021</b> , 38, 100989	11.3	21
32	Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis. <i>Hypertension</i> , <b>2020</b> , 76, 1563-1571	8.5	19
31	Less Severe but Prolonged Course of Acute Hepatitis A in Human Immunodeficiency Virus (HIV)-Infected Patients Compared With HIV-Uninfected Patients During an Outbreak: A Multicenter Observational Study. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1595-1602	11.6	18
30	Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. <i>PLoS ONE</i> , <b>2016</b> , 11, e0169228	3.7	14
29	Echinocandins as alternative treatment for HIV-infected patients with <i>Pneumocystis pneumonia</i> . <i>Aids</i> , <b>2019</b> , 33, 1345-1351	3.5	14
28	Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 35-42	14.3	12
27	Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection. <i>Hepatology International</i> , <b>2019</b> , 13, 431-439	8.8	11
26	Trends of recent hepatitis C virus infection among HIV-positive men who have sex with men in Taiwan, 2011-2018. <i>EClinicalMedicine</i> , <b>2020</b> , 24, 100441	11.3	11
25	Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2017</b> , 50, 595-603	8.5	10
24	Prevalence of and risk factor for community-onset third-generation cephalosporin-resistant <i>Escherichia coli</i> bacteremia at a medical center in Taiwan. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 245	4	10
23	Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194149	3.7	10
22	Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186338	3.7	9
21	Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection. <i>Liver International</i> , <b>2019</b> , 39, 1408-1417	7.9	9
20	Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-centre retrospective cohort in Taiwan. <i>BMJ Open</i> , <b>2019</b> , 9, e033246	3	9

19	Serological responses to revaccination against HBV in HIV-positive patients born in the era of nationwide neonatal HBV vaccination. <i>Liver International</i> , <b>2018</b> , 38, 1920-1929	7.9	8
18	Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2020</b> , 53, 936-945	8.5	8
17	Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2021</b> , 54, 228-237	8.5	7
16	Serological survey in close contacts with a confirmed case of H7N9 influenza in Taiwan. <i>Journal of Infection</i> , <b>2013</b> , 67, 494-5	18.9	6
15	Increasing New Delhi metallo-β-lactamase-positive <i>Escherichia coli</i> among carbapenem non-susceptible Enterobacteriaceae in Taiwan during 2016 to 2018. <i>Scientific Reports</i> , <b>2021</b> , 11, 2609	4.9	6
14	Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant <i>Acinetobacter baumannii</i> complex. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2015</b> , 48, 545-51	8.5	5
13	Colonization With Multidrug-Resistant Organisms Among Healthy Adults in the Community Setting: Prevalence, Risk Factors, and Composition of Gut Microbiome. <i>Frontiers in Microbiology</i> , <b>2020</b> , 11, 1402	5.7	5
12	Fungal Diseases in Taiwan-National Insurance Data and Estimation. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2019</b> , 5,	5.6	3
11	High rates of misidentification of uncommon <i>Candida</i> species causing bloodstream infections using conventional phenotypic methods. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 1179-1187	3.2	3
10	Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 105, 147-151	10.5	2
9	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 86, 473-481	3.1	2
8	Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 1269-1273	3.2	2
7	A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertiary care hospital in Taiwan. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> , 120, 1459-1463	3.2	2
6	Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: emerging role of genotype 6.. <i>Emerging Microbes and Infections</i> , <b>2022</b> , 1-26	18.9	2
5	Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	1
4	Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based combination antiretroviral therapy. <i>Medicine (United States)</i> , <b>2019</b> , 98, e16235	1.8	1
3	Seroepidemiology of the human herpesvirus 8 infection among people living with HIV in Taiwan, 2014-2018. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2021</b> , 54, 934-943	8.5	0
2	Hepatitis C microelimination among people living with HIV in Taiwan. <i>Emerging Microbes and Infections</i> , 1-29	18.9	0

- 1 Screening for Cryptococcal Antigenemia and Burden of Cryptococcosis at the Time of HIV  
Diagnosis: A Retrospective Multicenter Study. *Infectious Diseases and Therapy*, **2021**, 10, 1363-1377 6.2